FDA Inspection 1026805 — Novartis Pharma S.A.S. - Centre de Biotechnologie
The FDA completed an inspection of Novartis Pharma S.A.S. - Centre de Biotechnologie on September 12, 2017 in Huningue. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI) (VAI)
- End Date
- September 12, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Huningue (France)